ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China
- Conditions
- Diabetic Macular Edema
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT06548568
- Locations
- 🇨🇳
Xiamen Eye Center of Xiamen University /ID# 268172, Xiamen, Fujian, China
🇨🇳Henan Provincial Eye Hosptial /ID# 272424, Zhengzhou, Henan, China
🇨🇳West China Hospital of Sichuan University /ID# 273656, Chengdu, Sichuan, China
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 500
- Registration Number
- NCT06548542
- Locations
- 🇺🇸
Digestive Health Specialists /ID# 266216, Dothan, Alabama, United States
🇺🇸East View Medical Research /ID# 270377, Mobile, Alabama, United States
🇺🇸Southern California Res. Ctr /ID# 265549, Coronado, California, United States
A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality
- Conditions
- Skin Quality Deficit
- Interventions
- Device: JUVÉDERM® VOLITE™Other: Control
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 135
- Registration Number
- NCT06547125
- Locations
- 🇨🇳
China-Japan Friendship Hospital /ID# 260959, Beijing, Beijing, China
🇨🇳Peking University First Hospital /ID# 260957, Xicheng District, Beijing, China
🇨🇳Nanjing Drum Tower Hospital /ID# 260950, Nanjing, Jiangsu, China
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
- Conditions
- Migraine
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1000
- Registration Number
- NCT06543914
- Locations
- 🇺🇸
Neurology and Neurodiagnostics of Alabama /ID# 267614, Hoover, Alabama, United States
🇺🇸Barrow Neurological Institute - Dignity Health St. Joseph's Hosp and Medical Ctr /ID# 267610, Phoenix, Arizona, United States
🇺🇸Kenneth Martinez MD, A Medical Corp /ID# 267834, Aliso Viejo, California, United States
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT06524635
- Locations
- 🇺🇸
University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor, Michigan, United States
🇺🇸Physioseq, LLC /ID# 267266, Sacramento, California, United States
A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review
- Conditions
- Atopic Dermatitis (AD)
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06503536
- Locations
- 🇨🇳
Huashan Hospital affiliated to Fudan University /ID# 268259, Shanghai, Shanghai, China
A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT06487572
- Locations
- 🇺🇸
Clinical Pharmacology Of Miami /ID# 268219, Miami, Florida, United States
🇺🇸Acpru /Id# 267057, Grayslake, Illinois, United States
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT06487559
- Locations
- 🇨🇳
Henan Cancer Hospital /ID# 262098, Zhengzhou, Henan, China
🇨🇳Beijing Youan Hospital, Capital Medical University -No differernce with previous /ID# 261928, Beijing, Beijing, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 262443, Fuzhou, Fujian, China
A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: ABBV-668 ERDrug: ABBV-668 IR
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 25
- Registration Number
- NCT06477926
- Locations
- 🇺🇸
Acpru /Id# 266960, Grayslake, Illinois, United States
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1280
- Registration Number
- NCT06468228
- Locations
- 🇺🇸
Cahaba Dermatology & Skin Health Center /ID# 263795, Birmingham, Alabama, United States
🇺🇸Medical Dermatology Specialists /ID# 263394, Phoenix, Arizona, United States
🇺🇸Dermatology Trial Associates /ID# 264587, Bryant, Arkansas, United States